Risk factors
Glaukos (GKOS) risk factors
Item 1A of every Glaukos Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors28 risks7 new3 dropped12 reworded
Glaukos added risks regarding artificial intelligence adoption, 340B drug pricing rules, and recently approved Epioxa commercialization.
Filed Feb 23, 2026 - FY2024 10-K risk factors24 risks
Risk section is dominated by the commercialization and manufacturing risks of the newly launched iDose TR implant and iStent product lines. Heavy reliance on a single manufacturing facility in San Clemente, California creates substantial operational vulnerability. Extensive exposure to healthcare regulatory reforms, pricing pressures, and third-party reimbursement policies dictates financial viability.
Filed Feb 25, 2025